Rui Vision Announces Tens of Millions of RMB Series A2 Financing Led by Jinke Junchuang to Pioneer Myopia Control Innovation

VCBeat learned that recently, MetaVision announced the completion of a multi-million yuan A2 round of financing, which was exclusively invested by Beijing Jinke Hightech&Innovation Ventures Co.,Ltd. This round of financing will focus on the R&D iteration of the company's core products, acceleration of Class III medical device registration applications, and market channel expansion. WinX Capital served as the exclusive financial advisor for this round of financing.

MetaVision, in collaboration with the Eye Hospital of Wenzhou Medical University, released two group standards at the 2025 International Forum on Innovative Development of Visual Health (VisionChina2025): "Technical Specifications for Far-Field Electronic Display Terminals" and "Visual Health Technical Requirements for Display Products — Far-Field Electronic Display Terminals." This marks the company's further consolidation of its position as an industry standard-setter, completing the transition from technological innovator to rule-maker in the industry.

MetaVision, established in 2017, pioneered AI Optical Neuro-modulation technology, integrating artificial intelligence, optical engineering, neuroscience, and clinical optometry. Focusing on key dimensions such as dynamic defocus, photobiology, myopic defocus, and contrast, MetaVision develops digital modulation tools to drive the innovation of far-vision technology and a comprehensive suite of myopia management digital solutions.

The company's products include self-developed and produced distant viewing products such as the Vision Training Device D1, Vision Training Device MAX 2.0, and Distant Screen PLUS 2.0. These are equipped with MetaVision's independently and originally developed distant light defocus digital technology system. Using digital display devices as a medium, they achieve digitalization and personalization of optical defocus, LCA (Longitudinal Chromatic Aberration), contrast, and more through unique optical hardware and software technologies, enabling directional regulation of visual pathways.

Unlike traditional telescopic devices that only alleviate eye fatigue by physically extending images, MetaVision leverages the aforementioned technology to deeply integrate its products into high-frequency daily eye-use scenarios for children and adolescents. It imperceptibly transforms electronic screen usage into an eye-care process, significantly improving compliance and convenience for children. This effectively delays the onset and progression of myopia in young people, achieving a breakthrough from "passive relief" to "active regulation."

MetaVision Big Face Book Pupil D1 (Dynamic Digital Defocus Version)

MetaVision Conducts Multi-Center Clinical Research on Digital Technology for Defocused Light Projection; Over a Thousand Trials from Authoritative Institutions such as Beijing Tongren Hospital Affiliated to Capital Medical University and Wenzhou Medical University Eye Hospital Show that the Product Can Significantly Slow Myopia Progression and Effectively Control Axial Elongation, with Clinical Results Superior to Traditional Single-Focus Lenses and Defocus Lenses. For Example, One-Year Clinical Trial Results from Beijing Tongren Hospital Affiliated to Capital Medical University Show that the Combined Group Achieved a 50% Reduction in Axial Length, an 80% Decrease in Myopia Degree, and Cases of Mild Myopia Cured; A Real-World Study of Nearly 200 Cases over Six Months Shows that the Mean Change in Axial Length Was 0.038mm in the Experimental Group vs. 0.125mm in the Control Group. The Combined Solution Using the Defocused Light Screen Group Showed an Average 70.7% Greater Delay in Axial Elongation Compared to the Defocus Lens Group, with Regression of Refractive Error Observed in the Experimental Group at Six Months. These Data Not Only Validate the Effectiveness of the Technology but Also Serve as Core Evidence for Product Registration and Market Promotion.

Currently, the company is advancing long-term research to verify the safety and sustained efficacy of prolonged use, while building a complete trust system from clinical data to academic certification with the support of a top-tier expert team.

As an innovative pioneer in China's myopia prevention and control field for children and adolescents, MetaVision plays a core role in promoting the standardized development of the industry. On June 13, 2025, MetaVision, in collaboration with the Eye Hospital of Wenzhou Medical University, hosted the release conference for the two group standards—Technical Specifications for Far-Field Electronic Display Terminals and Visual Health Technical Requirements for Display Products – Far-Field Electronic Display Terminals—at the Xi'an International Conference Center. The event aims to provide scientific evidence for far-field display technology and advance the standardization process within the industry. These are the first domestic standards specifically targeting the far-field technology segment, marking MetaVision's technical solutions as industry benchmarks.

The funds from this round of financing will be mainly used in two major directions: (1)Medical Qualification Breakthrough: Promote the registration and application of Class III medical devices to further enhance the medical attributes of products and raise market access thresholds. (2)Technology Iteration and Scenario Expansion: Deepen the exploration of the regulatory mechanisms of light signals on brain visual neural pathways, expand the dual function of "eye protection + improving learning efficiency," and cover users across all age groups from 3 to 18 years old. At the same time, the company plans to build a closed-loop service system of "detection-training-feedback" through an online and offline integrated channel strategy. The company's products have been extended to over 400 cities in China and are available in more than 600 professional institutions.

Dr. Yao Jun, founder of MetaVision, said:We are very grateful for the recognition and support from our current round of investors. Through MetaVision's AI-driven integrated medical-grade digital solution of "eye-brain-light therapy + precision learning," we are redefining health and education scenarios for teenagers. We provide scientific, digital myopia prevention and control for children and adolescents, as well as digital full-lifecycle eye health management, ensuring that 170 million children and adolescents are free from worries about myopia and learning.

Dr. Sun Zhixing, Executive Director of Beijing Jinke Hightech&Innovation Ventures Co., Ltd., said:The myopia rate among children and adolescents in China remains persistently high, with the number of myopia cases continuing to rise. MetaVision has pioneered and actively promoted the development of the intelligent far-field light screen industry, integrating myopia prevention and control into high-frequency eye-use scenarios in the daily lives of children and adolescents. This effort holds significant social value and market potential. Through multidisciplinary technical exploration, MetaVision has continuously developed innovative technologies such as dynamic digital defocus and AI light-eye-brain neural regulation, which have demonstrated promising preventive effects in clinical studies and gained recognition and ongoing support from authoritative medical experts in the field. We are optimistic about MetaVision's continuous R&D capabilities and its proactive advancement in evidence-based medical research, leading the development path from serious medical applications to consumer-driven healthcare. We look forward to MetaVision providing revolutionary and highly efficient solutions for myopia prevention and control among children and adolescents in China through ongoing technological innovation and clinical research.

Beijing Jinke Hightech&Innovation Ventures Co.,Ltd. is a venture capital firm focused on early and mid-stage technology enterprise investments, primarily targeting technology-driven innovative companies to help transform scientific and technological achievements into commercial value. Its LPs include government funds such as the National Science and Technology Achievement Transformation Guidance Fund, Yingfu Taihe National Emerging Industry Venture Capital Guidance Fund, Beijing Science and Innovation Fund, Beijing Economic-Technological Development Zone Science and Innovation Guidance Fund, Beijing Changping SME Innovation and Entrepreneurship Fund, Beijing Daxing Development Guidance Fund, as well as continuously supportive private capital. Currently, Jinke Hightech&Innovation Ventures manages five venture capital funds, each with a duration of 8+2 years. The funds adhere to the principle of not following trends or blindly conforming, having invested in over 80 enterprises. Effective investment layouts have been carried out around directions such as healthcare and intelligent technology.

WinX Capital is a leading investment bank in China's large health industry, with headquarters in Beijing and Shanghai, and offices in Shenzhen and Hangzhou. It has been awarded numerous honors such as the "Top 1 Best Financial Advisor in the Medical and Health Field for 2024" by Qimingpian, "Top 1 Financial Advisory Institution in the Medical and Health Field for 2022-2024" by First Sound, and "Top 100 Future Healthcare · Annual Financial Advisor in Medical and Health" by VCBeat for 2022-2024.